ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used with or without methotrexate.
ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.
ENBREL is indicated for chronic moderate to severe plaque psoriasis (PsO) in children 4 years and older and adults who may benefit from taking injections or pills (systemic therapy) or phototherapy (ultraviolet light).
ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.
Rheumatoid Arthritis
Plaque Psoriasis
Psoriatic Arthritis
Ankylosing Spondylitis
Juvenile Idiopathic Arthritis (JIA)
Every person has a story. The Vibrant Lives program gives you a chance to share your story and help other people learn about your experiences with psoriatic arthritis and ENBREL. You may also have opportunities to speak at meetings for health care professionals, be featured in promotional materials (such as brochures and websites), and offer insights that help inform new patient materials.
Call 1-877-886-2808 between 8 AM and 5 PM (PT) to ask about participating in the Vibrant Lives program.
"ENBREL works for me. It helps me to do many of the things I like to do. It helps me to live my life with less pain."
Your results may vary.
—Brandon, ENBREL patient with psoriatic arthritis
Before being diagnosed with psoriatic arthritis in 2009, Brandon lived with joint pain for 10 years. He woke up each morning with stiffness and swelling in his hands, fingers, feet, and toes, making his life as a musician increasingly difficult. He even had surgery on his foot to try to relieve the pain. After that didn’t work, he tried an intensive ibuprofen regimen and methotrexate, but they provided little relief.
After Brandon started developing mild skin irritation, his wife persuaded him to see another doctor. It was a rheumatologist who made the connection between the joint pain and skin condition. After diagnosing him with psoriatic arthritis, Brandon’s doctor prescribed ENBREL. ENBREL helps reduce Brandon’s symptoms—including his pain—which allows him to be more active. Since starting ENBREL, Brandon has been able to do things that he thought he couldn’t do before starting treatment. Check with your doctor to see if ENBREL could help you. Your results may vary.
ENBREL works on your immune system and can make it harder to fight infections. Serious infections, like tuberculosis (TB) and infections caused by viruses, fungi, or bacteria, have happened in patients taking ENBREL. If you start to get an infection while you are taking ENBREL, tell your doctor right away.
Please see the full Prescribing Information, Important Safety Information, and Medication Guide for more details about ENBREL.
Eligibility Criteria: Open to patients who have an ENBREL prescription and who have commercial or private insurance, including plans available through state and federal healthcare exchanges. This program helps eligible patients cover out-of-pocket prescription costs for ENBREL up to program limits. There is no income requirement to participate in this program.
This offer is not valid for patients whose ENBREL prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs. It is not valid for cash-paying patients or where prohibited by law.
Effective January 1, 2018, the Enbrel® Co-Pay Card program does not cover out-of-pocket costs for any patient whose commercial insurance plan does not apply Enbrel® Co-Pay Card payments to satisfy the patient’s co-payment, deductible or coinsurance for ENBREL. Patients with these plan limitations are not eligible for the Enbrel® Co-Pay Card program but may be eligible for other needs-based assistance provided by Amgen. If you believe your commercial insurance plan may have such limitations, please contact Amgen’s administrator at 888-436-2735.
If at any time patients begin receiving prescription drug coverage under any state or government (including but not limited to Medicare, Medicaid, TRICARE, Department of Defense, or Veteran’s Affairs programs), patients will no longer be able to use this card and you must contact ENBREL Support® at 1-888-436- 2735 (8:00am-8:00pm eastern time, Monday-Friday) to stop your participation in this program.
Patients may not seek reimbursement for the value received from the Enbrel® Co-Pay Card from any third-party payers, including a flexible spending account or healthcare savings account. Participating in this program means that you are ensuring you comply with any co-payment disclosure of your insurance carrier or pharmacy benefit manager. Restrictions may apply. Offer subject to change or discontinuation without notice. This is not health insurance.
Program Details: For all eligible patients, the Enbrel® Co-Pay Card may offer:
The program provides up to $12,000 of assistance per patient for each calendar year, which must be applied to out-of-pocket prescription costs for ENBREL. Each patient is responsible for costs above these amounts. Patients may use the card every time they fill their ENBREL prescription. Benefits reset each calendar year. Enrollment in the program is for 12 months. Patients may continue in the program after that by renewing enrollment every 12 months. Patients can enroll by visiting EnbrelSupport.com or by calling 1-888-436-2735 and selecting option 1.
ENBREL is a medicine that affects your immune system. ENBREL can lower the ability of your immune system to fight infections. Serious infections have happened in patients taking ENBREL. These infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some patients have died from these infections. Your healthcare provider should test you for TB before you take ENBREL and monitor you closely for TB before, during, and after ENBREL treatment, even if you have tested negative for TB.
There have been some cases of unusual cancers, some resulting in death, reported in children and teenage patients who started using tumor necrosis factor (TNF) blockers before 18 years of age. Also, for children, teenagers, and adults taking TNF blockers, including ENBREL, the chances of getting lymphoma or other cancers may increase. Patients with RA may be more likely to get lymphoma.
ENBREL can cause serious side effects including: New infections or worsening of infections you already have; hepatitis B can become active if you already have had it; nervous system problems, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes; blood problems (some fatal); new or worsening heart failure; new or worsening psoriasis; allergic reactions; autoimmune reactions, including a lupus-like syndrome and autoimmune hepatitis.
Common side effects include: Injection site reactions and upper respiratory infections (sinus infections).
In general, side effects in children were similar in frequency and type as those seen in adult patients. The types of infections reported were generally mild and similar to those usually seen in children.
These are not all the side effects with ENBREL. Tell your healthcare provider about any side effect that bothers you or does not go away.
If you have any questions about this information, be sure to discuss them with your healthcare provider. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see Prescribing Information and Medication Guide.
ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.
ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.
ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used with or without methotrexate.
ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
ENBREL is indicated for chronic moderate to severe plaque psoriasis (PsO) in children 4 years and older and adults who may benefit from taking injections or pills (systemic therapy) or phototherapy (ultraviolet light).
ENBREL is a medicine that affects your immune system. ENBREL can lower the ability of your immune system to fight infections. Serious infections have happened in patients taking ENBREL. These infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some patients have died from these infections. Your healthcare provider should test you for TB before you take ENBREL and monitor you closely for TB before, during, and after ENBREL treatment, even if you have tested negative for TB.
There have been some cases of unusual cancers, some resulting in death, reported in children and teenage patients who started using tumor necrosis factor (TNF) blockers before 18 years of age. Also, for children, teenagers, and adults taking TNF blockers, including ENBREL, the chances of getting lymphoma or other cancers may increase. Patients with RA may be more likely to get lymphoma.
ENBREL can cause serious side effects including: New infections or worsening of infections you already have; hepatitis B can become active if you already have had it; nervous system problems, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes; blood problems (some fatal); new or worsening heart failure; new or worsening psoriasis; allergic reactions; autoimmune reactions, including a lupus-like syndrome and autoimmune hepatitis.
Common side effects include: Injection site reactions and upper respiratory infections (sinus infections).
In general, side effects in children were similar in frequency and type as those seen in adult patients. The types of infections reported were generally mild and similar to those usually seen in children.
These are not all the side effects with ENBREL. Tell your healthcare provider about any side effect that bothers you or does not go away.
If you have any questions about this information, be sure to discuss them with your healthcare provider. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see Prescribing Information and Medication Guide.
ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.
ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.
ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used with or without methotrexate.
ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
ENBREL is indicated for chronic moderate to severe plaque psoriasis (PsO) in children 4 years and older and adults who may benefit from taking injections or pills (systemic therapy) or phototherapy (ultraviolet light).
ENBREL is a medicine that affects your immune system. ENBREL can lower the ability of your immune system to fight infections. Serious infections have happened in patients taking ENBREL. These infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some patients have died from these infections. Your healthcare provider should test you for TB before you take ENBREL and monitor you closely for TB before, during, and after ENBREL treatment, even if you have tested negative for TB.
There have been some cases of unusual cancers, some resulting in death, reported in children and teenage patients who started using tumor necrosis factor (TNF) blockers before 18 years of age. Also, for children, teenagers, and adults taking TNF blockers, including ENBREL, the chances of getting lymphoma or other cancers may increase. Patients with RA may be more likely to get lymphoma.
ENBREL can cause serious side effects including: New infections or worsening of infections you already have; hepatitis B can become active if you already have had it; nervous system problems, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes; blood problems (some fatal); new or worsening heart failure; new or worsening psoriasis; allergic reactions; autoimmune reactions, including a lupus-like syndrome and autoimmune hepatitis.
Common side effects include: Injection site reactions and upper respiratory infections (sinus infections).
In general, side effects in children were similar in frequency and type as those seen in adult patients. The types of infections reported were generally mild and similar to those usually seen in children.
These are not all the side effects with ENBREL. Tell your healthcare provider about any side effect that bothers you or does not go away.
If you have any questions about this information, be sure to discuss them with your healthcare provider. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see Prescribing Information and Medication Guide.
ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.
ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.
ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used with or without methotrexate.
ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
ENBREL is indicated for chronic moderate to severe plaque psoriasis (PsO) in children 4 years and older and adults who may benefit from taking injections or pills (systemic therapy) or phototherapy (ultraviolet light).